Ultragenyx Pharmaceutical reported $160M in Sales Revenues for its fiscal quarter ending in September of 2025.





Sales Change Date
Acadia Pharmaceuticals USD 278.6M 14M Sep/2025
Agios Pharmaceuticals USD 12.9M 450K Sep/2025
Alnylam Pharmaceuticals USD 1.25B 476.31M Sep/2025
BioMarin Pharmaceutical USD 776M 49M Sep/2025
Insmed USD 142M 34.6M Sep/2025
Ionis Pharmaceuticals USD 157M 295M Sep/2025
Kyowa Hakko Kirin JPY 118.8B 7.13B Sep/2025
MacroGenics USD 72.84M 50.6M Sep/2025
Moderna USD 1.02B 878M Sep/2025
Neurocrine Biosciences USD 794.9M 107.4M Sep/2025
PTC Therapeutics USD 211M 32.1M Sep/2025
Regeneron Pharmaceuticals USD 3.88B 130M Dec/2025
Sarepta Therapeutics USD 399.4M 211.69M Sep/2025
Ultragenyx Pharmaceutical USD 160M 6.5M Sep/2025
Vertex Pharmaceuticals USD 3.08B 120M Sep/2025